| Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma (NCT05227144) | ORIC Pharmaceuticals | 2022-01-06 |
| SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (NCT04684108) | Hangzhou Sumgen Biotech Co., Ltd. | 2021-11-04 |
| Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM (NCT05052970) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2021-10-20 |
| A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (NCT04939142) | Antengene Corporation | 2021-07-12 |
| A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma (NCT05011097) | Wuhan YZY Biopharma Co., Ltd. | 2021-07-08 |
| A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma (NCT04735575) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2021-05-20 |
| Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma (NCT04706936) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-04-01 |
| MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma (NCT04798586) | Pfizer | 2021-03-22 |
| Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet (NCT04191616) | Amgen | 2020-08-06 |
| CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT04626752) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-04-01 |
| Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma (NCT04194931) | The First Affiliated Hospital of Nanchang University | 2019-12-01 |
| INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma (NCT03837509) | Incyte Corporation | 2019-09-25 |
| Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia (NCT03755154) | Institut de Recherches Internationales Servier | 2019-07-17 |
| A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (NCT03859427) | Amgen | 2019-05-08 |
| A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma (NCT03815383) | The First Affiliated Hospital with Nanjing Medical University | 2019-04-11 |
| A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma (NCT03751293) | Hebei Yanda Ludaopei Hospital | 2019-01-08 |
| Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients (NCT03464916) | Sorrento Therapeutics, Inc. | 2018-10-15 |
| Selinexor, Cyclophosphamide and Prednisone in Myeloma (NCT06212596) | University of Leeds | 2018-07-16 |
| A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers (NCT03512353) | Amgen | 2018-07-05 |
| Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma (NCT02939183) | Amgen | 2017-01-17 |
| AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia (NCT02675452) | Amgen | 2016-06-13 |
| BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) (NCT02834364) | University of Heidelberg Medical Center | 2016-06-01 |
| Study of BEBT-908 in Subjects With Advanced Hematological Tumors (NCT06082596) | BeBetter Med Inc | 2016-03-02 |
| QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma (NCT02099539) | Altor BioScience | 2014-10-06 |
| Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide (NCT02046915) | University Hospital Tuebingen | 2014-04-01 |
| Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma (NCT02075021) | NYU Langone Health | 2014-03-01 |
| Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma (NCT01866293) | Memorial Sloan Kettering Cancer Center | 2013-05-28 |
| QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma (NCT01670994) | Altor BioScience | 2012-08-14 |
| Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation (NCT01058434) | Novartis Pharmaceuticals | 2010-05-01 |
| Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) (NCT00773838) | Merck Sharp & Dohme LLC | 2008-12-01 |
| A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. (NCT00708292) | Novartis Pharmaceuticals | 2008-07-01 |
| Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) (NCT00642954) | Merck Sharp & Dohme LLC | 2008-02-13 |
| A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma (NCT00478777) | Celgene Corporation | 2007-03-01 |
| A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma (NCT00545519) | Washington University School of Medicine | 2006-10-01 |
| Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients (NCT05463939) | Janssen Research & Development, LLC | |
| Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma (NCT05757973) | Janssen Research & Development, LLC | |
| Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma (NCT05503550) | Janssen Research & Development, LLC | |